Monoclonal Antibodies

Cancer cells express a variety of antigens that are attractive targets for monoclonal antibody-based therapy (Table 51-3). Several monoclonal antibodies are FDA-approved for treating lymphoid and solid tumor malignancies, including rituximab and alemtuz,umab for lymphoid malignancies, and trastuzumab for breast cancer. Because murine monoclonal antibodies have a short t1/2 and induce a human anti-mouse antibody immune response, they usually are chimerized or humanized when used as therapeutic agents. The nomenclature adopted for therapeutic monoclonal antibodies is to terminate the name in -ximab for chimeric antibodies and -umab for humanized antibodies. A variety of mechanism(s) of cell killing have been described for naked monoclonal antibodies, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and direct induction of apoptosis, but the clinically relevant mechanisms remain uncertain. Monoclonal antibodies also may be engineered to combine the antibody with a toxin (immunotoxins), such as gemtuzumab ozogamicin (mylotarg) or denileukin diftitox (ontak), or combined with a radioactive isotope, as in the case of 90Y-ibritumomab tiuxetan (zevalin) (Table 51-3). More recently, antibodies have been engineered to contain a second specificity, known as bi-specific antibodies.

Delicious Diabetic Recipes

Delicious Diabetic Recipes

This brilliant guide will teach you how to cook all those delicious recipes for people who have diabetes.

Get My Free Ebook

Post a comment